Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Results from the British Society for Rheumatology Biologics Register

71Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

Abstract

Objective. To describe working status in patients with RA, AS and PsA treated with anti-TNF therapy registered with the British Society for Rheumatology Biologics Register. Methods. Patients with RA (n = 3291), AS (n = 229) and PsA (n = 254) treated with anti-TNF therapy were included in this study. In addition, biologic-naive patients with RA (n = 379) were included. At baseline and 3 years after registration, all patients reported their working status. Baseline characteristics between working and work-disabled patients were compared. Logistic regression analysis was applied to identify factors associated with new work disability in patients with RA. Results. At baseline, work disability rates were already high: 49% for RA, 39% for PsA, 41% for AS and 36% for biologic-naive patients. Work-disabled patients had a higher HAQ score and worse disease activity than working patients. Working patients with a high HAQ score [odds ratio (OR) 2.79; 95% CI 1.89, 4.12] and a manual job (OR 2.31; 95% CI 1.52, 3.52) at baseline were more likely to become work disabled at follow-up, while those patients in remission 6 months after commencing anti-TNF therapy were less likely to become work disabled. However, use of anti-TNF therapy did not prevent patients with RA from becoming work disabled (OR for RA control patients vs RA anti-TNF patients 0.80; 95% CI 0.36, 1.81, adjusted for baseline variables). Conclusion. A high percentage of patients with RA, AS and PsA were already work disabled at the start of anti-TNF therapy. There is less future work disability in working patients with RA who responded to anti-TNF therapy. © The Author(s) 2010.

References Powered by Scopus

Modified disease activity scores that include twenty‐eight‐joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

5515Citations
N/AReaders
Get full text

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial

2352Citations
N/AReaders
Get full text

Multiple imputation of missing blood pressure covariates in survival analysis

1748Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force

387Citations
N/AReaders
Get full text

Managing patients with psoriatic disease: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

217Citations
N/AReaders
Get full text

Work disability in psoriatic arthritis: A systematic review

97Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Verstappen, S. M. M., Watson, K. D., Lunt, M., McGrother, K., Symmons, D. P. M., & Hyrich, K. L. (2010). Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology, 49(8), 1570–1577. https://doi.org/10.1093/rheumatology/keq131

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 25

50%

Researcher 18

36%

Lecturer / Post doc 4

8%

Professor / Associate Prof. 3

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 38

79%

Nursing and Health Professions 4

8%

Agricultural and Biological Sciences 4

8%

Pharmacology, Toxicology and Pharmaceut... 2

4%

Save time finding and organizing research with Mendeley

Sign up for free
0